drugset / Trial / NCT04568304

A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

NCT04568304

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally advanced or metastatic urothelial carcinoma who have received no previous systemic therapy.

Timeline

Start
2022-09-06
Primary completion
2022-09-06
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Toripalimab Monoclonal antibody 240 mg Intravenous
Background Carboplatin Small molecule 4.5 unknown Intravenous
Background Cisplatin Other / unclassified 70 mg/m2 Intravenous
Background Gemcitabine Small molecule 1000 mg Intravenous

Indications